BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dzobo K, Senthebane DA, Ganz C, Thomford NE, Wonkam A, Dandara C. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells 2020;9:E1896. [PMID: 32823711 DOI: 10.3390/cells9081896] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Ivanova EL, Costa B, Eisemann T, Lohr S, Boskovic P, Eichwald V, Meckler J, Jugold M, Orian-rousseau V, Peterziel H, Angel P. CD44 expressed by myeloid cells promotes glioma invasion. Front Oncol 2022;12:969787. [DOI: 10.3389/fonc.2022.969787] [Reference Citation Analysis]
2 Zhou S, Hassan A, Kungyal T, Tabariès S, Luna JLRG, Siegel PM, Philip A. CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells. Cancers 2022;14:3672. [DOI: 10.3390/cancers14153672] [Reference Citation Analysis]
3 Rath S, Chakraborty D, Pradhan J, Imran Khan M, Dandapat J. Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy. Cytokine 2022;157:155967. [PMID: 35905624 DOI: 10.1016/j.cyto.2022.155967] [Reference Citation Analysis]
4 Sharma V, Letson J, Furuta S. Fibrous stroma: Driver and passenger in cancer development. Sci Signal 2022;15:eabg3449. [PMID: 35258999 DOI: 10.1126/scisignal.abg3449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aydin B, Yildirim E, Erdogan O, Arga KY, Yilmaz BK, Bozkurt SU, Bayrakli F, Turanli B. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance. OMICS 2022;26:115-29. [PMID: 35172108 DOI: 10.1089/omi.2021.0221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xiao Y, Yang K, Wang Z, Zhao M, Deng Y, Ji W, Zou Y, Qian C, Liu Y, Xiao H, Liu H. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression. Front Surg 2022;8:775194. [DOI: 10.3389/fsurg.2021.775194] [Reference Citation Analysis]
7 Yang Y, Meng WJ, Wang ZQ. Cancer Stem Cells and the Tumor Microenvironment in Gastric Cancer. Front Oncol 2021;11:803974. [PMID: 35047411 DOI: 10.3389/fonc.2021.803974] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Filipiak-Duliban A, Brodaczewska K, Kajdasz A, Kieda C. Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models. Int J Mol Sci 2022;23:1166. [PMID: 35163092 DOI: 10.3390/ijms23031166] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hong S, Song JM. 3D bioprinted drug-resistant breast cancer spheroids for quantitative in situ evaluation of drug resistance. Acta Biomater 2022;138:228-39. [PMID: 34718182 DOI: 10.1016/j.actbio.2021.10.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xiao Y, Wang Z, Zhao M, Ji W, Xiang C, Li T, Wang R, Yang K, Qian C, Tang X, Xiao H, Zou Y, Liu H. . MBE 2022;19:9481-504. [DOI: 10.3934/mbe.2022441] [Reference Citation Analysis]
11 Kishi M, Asgarova A, Desterke C, Chaker D, Artus J, Turhan AG, Bennaceur-Griscelli A, Griscelli F. Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. Front Med (Lausanne) 2021;8:729018. [PMID: 34957134 DOI: 10.3389/fmed.2021.729018] [Reference Citation Analysis]
12 Sadanandan N, Shear A, Brooks B, Saft M, Cabantan DAG, Kingsbury C, Zhang H, Anthony S, Wang ZJ, Salazar FE, Lezama Toledo AR, Rivera Monroy G, Vega Gonzales-Portillo J, Moscatello A, Lee JY, Borlongan CV. Treating Metastatic Brain Cancers With Stem Cells. Front Mol Neurosci 2021;14:749716. [PMID: 34899179 DOI: 10.3389/fnmol.2021.749716] [Reference Citation Analysis]
13 Zhuang Z, Cai H, Lin H, Guan B, Wu Y, Zhang Y, Liu X, Zhuang J, Guan G. Development and Validation of a Robust Pyroptosis-Related Signature for Predicting Prognosis and Immune Status in Patients with Colon Cancer. J Oncol 2021;2021:5818512. [PMID: 34840571 DOI: 10.1155/2021/5818512] [Reference Citation Analysis]
14 Chaves LP, Melo CM, Saggioro FP, Reis RBD, Squire JA. Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics. Genes 2021;12:1900. [DOI: 10.3390/genes12121900] [Reference Citation Analysis]
15 Zhang X, Liu D, Gao Y, Lin C, An Q, Feng Y, Liu Y, Liu D, Luo H, Wang D. The Biology and Function of Extracellular Vesicles in Cancer Development. Front Cell Dev Biol 2021;9:777441. [PMID: 34805181 DOI: 10.3389/fcell.2021.777441] [Reference Citation Analysis]
16 Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines 2021;9:1591. [PMID: 34829820 DOI: 10.3390/biomedicines9111591] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med 2021;25:9891-904. [PMID: 34585512 DOI: 10.1111/jcmm.16939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Horst EN, Bregenzer ME, Mehta P, Snyder CS, Repetto T, Yang-Hartwich Y, Mehta G. Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. Acta Biomater 2021;132:401-20. [PMID: 33940195 DOI: 10.1016/j.actbio.2021.04.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. Biofactors 2021. [PMID: 34375483 DOI: 10.1002/biof.1776] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
20 Mu Q, Najafi M. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol 2021;907:174365. [PMID: 34302814 DOI: 10.1016/j.ejphar.2021.174365] [Reference Citation Analysis]
21 Dzobo K. Integrins Within the Tumor Microenvironment: Biological Functions, Importance for Molecular Targeting, and Cancer Therapeutics Innovation. OMICS 2021;25:417-30. [PMID: 34191612 DOI: 10.1089/omi.2021.0069] [Reference Citation Analysis]
22 Ghaderi F, Jokar N, Gholamrezanezhad A, Assadi M, Ahmadzadehfar H. Toward radiotheranostics in cancer stem cells: a promising initial step for tumour eradication. Clin Transl Imaging 2021;9:561-78. [DOI: 10.1007/s40336-021-00444-x] [Reference Citation Analysis]
23 Wang J, Hao JP, Uddin MN, Wu Y, Chen R, Li DF, Xiong DQ, Ding N, Yang JH, Ding XS. Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia. Aging (Albany NY) 2021;13:16445-70. [PMID: 34148032 DOI: 10.18632/aging.203166] [Reference Citation Analysis]
24 Hua Z, White J, Zhou J. Cancer stem cells in TNBC. Semin Cancer Biol 2021:S1044-579X(21)00185-1. [PMID: 34147641 DOI: 10.1016/j.semcancer.2021.06.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Keyvani-Ghamsari S, Khorsandi K, Rasul A, Zaman MK. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics 2021;13:120. [PMID: 34051847 DOI: 10.1186/s13148-021-01107-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Dzobo K, Sinkala M. Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis. OMICS 2021;25:313-32. [PMID: 33961518 DOI: 10.1089/omi.2021.0025] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Hao S, Zhu X, Liu Z, Wu X, Li S, Jiang P, Jiang L. Chronic intermittent hypoxia promoted lung cancer stem cell-like properties via enhancing Bach1 expression. Respir Res 2021;22:58. [PMID: 33596919 DOI: 10.1186/s12931-021-01655-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Shingai Y, Yokota T, Okuzaki D, Sudo T, Ishibashi T, Doi Y, Ueda T, Ozawa T, Nakai R, Tanimura A, Ichii M, Shibayama H, Kanakura Y, Hosen N. Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. Stem Cells 2021;39:723-36. [PMID: 33539590 DOI: 10.1002/stem.3348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Gao XY, Zang J, Zheng MH, Zhang YF, Yue KY, Cao XL, Cao Y, Li XX, Han H, Jiang XF, Liang L. Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma. Front Cell Dev Biol 2021;9:620883. [PMID: 33614649 DOI: 10.3389/fcell.2021.620883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
30 Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers (Basel) 2020;12:E3801. [PMID: 33348546 DOI: 10.3390/cancers12123801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
31 Kharkar PS. Cancer Stem Cell (CSC) Inhibitors in Oncology-A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives. J Med Chem 2020;63:15279-307. [PMID: 33325699 DOI: 10.1021/acs.jmedchem.0c01336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
32 Azizi Machekposhti S, Movahed S, Narayan RJ. Physicochemical parameters that underlie inkjet printing for medical applications. Biophysics Rev 2020;1:011301. [DOI: 10.1063/5.0011924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Hosono H, Ohishi T, Takei J, Asano T, Sayama Y, Kawada M, Kaneko MK, Kato Y. The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncol Lett 2020;20:383. [PMID: 33154781 DOI: 10.3892/ol.2020.12246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]